EGFR and neoplasm: Furthermore, we employed two osimertinib-resistant PDX (PDX-1R, PDX-2R) with no other TKI-resistant related alterations detected except the original EGFR Ex19Del and found the bortezomib combined with osimertinib treatment significantly inhibited the tumor growth (Fig. 6f, g).